Press Releases

Date Title and Summary View
November 9, 2017 Eleven Biotherapeutics to Report Third Quarter 2017 Financial Results on November 14, 2017
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 9, 2017-- Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a late-stage clinical oncology company advancing novel product candidates based on its Targeted Protein Therapeutics (TPTs) platform, today announced it will host a live conference call and webcast at
View HTML
November 9, 2017 Eleven Biotherapeutics to Present at Stifel 2017 Healthcare Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 9, 2017-- Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a late-stage clinical oncology company advancing novel product candidates based on its Targeted Protein Therapeutics (TPTs) platform, today announced that Stephen Hurly, President and Chief Executive
View HTML
November 3, 2017 Eleven Biotherapeutics Announces Closing of $8.0 Million Underwritten Public Offering
CAMBRIDGE, Mass --(BUSINESS WIRE)--Nov. 3, 2017-- Eleven Biotherapeutics, Inc. (“Eleven” or the “Company”) (NASDAQ:EBIO), a late-stage clinical oncology company advancing novel product candidates based on its Targeted Protein Therapeutics (TPTs) platform, today announced the closing of the
View HTML
November 1, 2017 Eleven Biotherapeutics Prices of $8.0 Million Underwritten Public Offering
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 1, 2017-- Eleven Biotherapeutics, Inc. (“Eleven” or the “Company”) (NASDAQ:EBIO), a late-stage clinical oncology company advancing novel product candidates based on its Targeted Protein Therapeutics (TPTs) platform, today announced the pricing of an
View HTML
October 13, 2017 Eleven Biotherapeutics Appoints Richard Fitzgerald as Interim Chief Financial Officer
-- Brings extensive capital raising and transaction experience to Eleven’s management team -- CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 13, 2017-- Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a late-stage clinical oncology company advancing novel product candidates based on its Targeted Protein
View HTML
September 22, 2017 Eleven Biotherapeutics Announces Completion of Vicinium Manufacturing for Ongoing Clinical Trials in Non-Muscle Invasive Bladder Cancer
-- Topline Three-Month Data from Phase 3 Registration Trial Expected in Mid-2018 -- CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 22, 2017-- Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a late-stage clinical oncology company advancing novel product candidates based on its Targeted Protein Therapeutics
View HTML
September 5, 2017 Eleven Biotherapeutics to Present at the Rodman & Renshaw 19th Annual Global Investment Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 5, 2017-- Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a late-stage clinical oncology company advancing a broad pipeline of novel product candidates based on its Targeting Protein Therapeutics (TPTs) platform, today announced that Stephen Hurly, President and
View HTML
August 14, 2017 Eleven Biotherapeutics Reports Second Quarter 2017 Financial Results
-- Announced Data and Safety Monitoring Board Recommendation to Continue Phase 3 Registration Trial of Vicinium™ as Planned -- -- Entered Collaboration with National Cancer Institute and AstraZeneca to Evaluate Vicinium in Combination with Imfinzi™ (Durvalumab) in Patients with Non-Muscle Invasive
View HTML
August 7, 2017 Eleven Biotherapeutics to Report Second Quarter 2017 Financial Results on Monday, August 14, 2017 View HTML
August 3, 2017 Eleven Biotherapeutics to Present at Canaccord Genuity 37th Annual Growth Conference View HTML